Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research
Completed Award

Dr. Malcolm Leissring

Malcolm Leissring, Ph.D.

Mayo Clinic Jacksonville
Jacksonville, FL

Title: Catabolism Of Amyloid Beta And Tau By Cathepsin D In Vivo
Non-Technical Title: Can Alzheimer Disease Be Treated With The Enzyme Cathepsin D?

Duration: April 1, 2009 - March 31, 2012
Award Type: Standard
Award Amount: $400,000

Summary:

We have discovered that deletion of an enzyme known as cathepsin D (CatD) in mice results in very large and very selective increases in the two toxic protein species that are most closely linked to two characteristics of Alzheimer's disease (AD): (1) the amyloid beta-protein (specifically the 42-amino acid form, amyloid beta42), which deposits in the extracellular "plaques" that characterize AD, and (2) the microtubule-associated protein, tau, which makes up the neurofibrillary tangles that form inside neurons in AD and other diseases. We hypothesize that CatD plays a protective role in preventing AD by (directly or indirectly) breaking down amyloid beta42 and tau. We will test this hypothesis by increasing or decreasing CatD levels in mice that accumulate either amyloid beta 42 or tau.

Details:


The brains of patients with Alzheimer's disease (AD) are characterized by abnormal accumulations of "plaques," which are extracellular deposits composed primarily of a protein fragment known as amyloid beta 42 and "tangles," which are fibrils that form inside neurons that are composed principally of a different protein known as tau. We have discovered that both of these proteins are destroyed by a specific enzyme known as cathepsin D (CatD), a finding that suggests it would play a protective role in preventing AD. Surprisingly, however, many years of research on the role of CatD in AD suggest that it might instead contribute to the disease. To discriminate between these two possibilities, we will increase or decrease CatD levels in mice that accumulate either amyloid beta42 or tau, then determine what the results are. If CatD is protective, as we hypothesize, then it might be possible to treat AD by increasing CatD levels with novel drugs, or by introducing the enzyme into patients directly.

Progress Updates:

This award supported a study investigating the role of an enzyme known as Cathepsin D (CatD) in Alzheimer's disease (AD). Dr. Leissring’s team found that CatD potently destroys the two major, toxic proteins that accumulate excessively in AD: the amyloid ß-protein (Aß), the major constituent of "senile plaques" that litter the brains of AD patients, and the tau protein, which makes up "tangles" that kill off brain cells in AD and other disorders. Deleting the gene for CatD in a mouse model of AD resulted in the largest increase in Aß ever recorded, the formation of exceptionally large plaques at very early ages, and also led to changes to the tau protein. The team’s findings are all consistent with a protective role for CatD in the disease process. Collectively, the team in this study identified a major new player in the complex process that leads to Alzheimer's disease. The research completed by Dr. Leissring’s team will help to assist in the diagnosis, detection, prevention and, hopefully, development of successful treatments for this devastating brain disorder. During the first reporting period of this award, which covers ~10 months of activity, we accomplished four major goals. First, we delivered a gene-changing treatment that increased the activity of CatD in non-AD mice and quantified the degree of that increase in terms of overall levels and activity of CatD, and whether this results in premature death. Second, we attempted the same genetic increase in CatD expression/activity in our first mouse model of AD (the results of which will be available within a few months). Third, we created a new genetic-changing treatment that is intended to reduce activity of CatD and characterized its effects in cultured cells. Fourth, we prepared and bred a second mouse model of AD mice that will be required to complete this project. Finally—in very significant advances that are exceptionally important to this project, but not explicitly part of the specific aims—we made significant progress characterizing mice that lack CatD (a third model), determining the underlying mechanism that affects beta-amyloid. We also analyzed mutations in human cathepsin D. Data from both of these experiments in the fourth goal suggest that CatD is significantly associated with a risk for late-onset AD.